At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Purpose
This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants will then track for 28 days to assess for any additional medical care needed or if hospitalization was required.
Condition
- Covid19
Eligibility
- Eligible Ages
- Over 65 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- UnitedHealthcare member - confirmed COVID-19 positive - located in an area where Bamlanivimab (LY3819253) is available for infusion
Exclusion Criteria
- current (from first symptom report) hospitalization for COVID-19 - prior administration of Bamlanivimab or other COVID-19 therapies - previous COVID-19 diagnosis - prior receipt of a COVID-19 vaccine - not authorized for patient use per the EUA
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Intervention Model Description
- Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab.
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Participants with COVID-19 |
Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse. |
|
Recruiting Locations
More Details
- NCT ID
- NCT04656691
- Status
- Terminated
- Sponsor
- Daniel Griffin